Vascugen

VascVersa's ANGICYTE™ Technology provides a revolutionary Cell Therapy for blood vessel regeneration. At VascVersa, we are committed to developing innovative regenerative medicine, to deliver a profound improvement to the lives of many individuals suffering from debilitating ischaemic diseases. It stimulates new blood vessel formation leading to improved blood supply & long term healing. Our first product will provide a new therapeutic solution for the active wound care market. Spun out of Queen's University Belfast and built on over 20 years of research. It can also provide a vital source of blood vessel cells for researchers studying angiogenesis or can be used to discover new drug therapies for cancer.

We are visionaries and realists in the right proportions. We are after the holy grail of bringing tissue-engineered medical products to patients AND have a deep bench of expertise in what it takes to run a successful medical device company. Vascudyne was founded by Jeff Franco and Kem Schankereli after a successful exit from Tendyne. Vascudyne leadership brings unique and minimally invasive delivery expertise alongside stent design technology for cardiovascular devices. Vascudyne licensed the engineered tissue technology from the University of Minnesota in December of 2018 and has been on a mission to accelerate its commercialization and get the technology out of the lab and into the hands of surgeons to benefit the millions of patients in need of replacement and repair tissues. Zeeshan Syedain joined Vascudyne as its Chief Scientific Officer in 2021 in perfect alignment with the company’s mission: to improve patient care with regenerative biomaterials that are inspired by nature. And that is what Vascudyne is developing: TRUE Tissue technology that is inspired by nature. The Vascudyne team is not just passionate about TRUE™ Tissue technology.

Vasgen Ltd is a recently formed UK biotech company based in London. Vasgen is developing a strong and dynamic team of experts including scientists and clinicians with an international reputation in translational and clinical research, who will provide the leadership to navigate the company through its development programmes and business cycles. Vasgen is currently seeking investors and partners to support development of its main pre-clinical programme and to facilitate an R & D programme to validate ADAMs and other metzincins of therapeutic interest. Founded by Dr’s Salman Rahman & Yatin Patel in 2011, Vasgen is committed to delivering a new generation of innovative and targeted therapeutics and in doing so hopes to provide more effective and personalised therapies for debilitating and life-threatening diseases. AbIMP® is a novel discovery platform that utilises monoclonal antibodies as selective inhibitors of previously intractable metzincin protease targets thereby offering new possibilities… Read more ». ADAM15 is a “sheddase” known to promote pathological angiogenesis in models of ocular neovascular disease and whose expression correlates strongly with the progression… Read more ». London UK, 19th August 2022: Vasgen Limited (“Vasgen” or “the Company”), a speciality biotech company, reports successfully competing in the Hertfordshire Science Partnership… Read more ». London UK, 17th July 2017: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it has successfully completed proof… Read more ».

Our mission is to make personalized cell therapy a reality for patients worldwide, providing accessible treatments to various unmet needs. Meet the people behind BioGenCell: A Group of Dedicated BioMed, Healthcare, Vascular and Business Professionals, Including a Nobel Prize Laureate and World-Renowned Scientists. BioGenCell is dedicated to changing the lives of patients suffering from degenerative microvascular diseases, stopping disease progression, reversing disability, reducing pain, and enhancing functionality. BioGenCell’s groundbreaking cell-therapy treatments aim to provide more accessible, reliable and cost-effective therapeutic options, with the hope of significantly impacting these tragic figures. BioGenCell’s Phase 2 Clinical Trial assesses the safety and efficacy of the BGC101 cell therapy in treating Chronic Limb-Threatening Ischemia. Since its inception in 2008, BioGenCell has been committed to transforming the lives of patients with degenerative diseases through advanced cell therapy treatments, based on the Company’s groundbreaking TRACT technology that uses a patient’s own blood as personalized medicine. Our innovative TRACT technology allows for stem cell therapies that are patient-friendly and physician-friendly. Through advanced, standardized procedures, we are dedicated to bringing transformative cell therapy treatments to vascular physicians and surgeons, podiatrists, and various other healthcare providers and clinicians.

Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery. Although AV grafts offer an alternative to fistula for patients with small or weak veins, it increases the risk of blood clotting, aneurysms, and infections. Sirogen™ is a bioabsorbable implant that delivers a well-known drug called sirolimus to blood vessels.

We are a seasoned and passionate team, committed to developing high impact and life changing therapies which heal the heart. We are a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. Elsley founded Vasogen Inc., a biotechnology company focused on the research and commercial development of novel therapeutics for the treatment of heart failure and other inflammatory conditions. Waddick is a CPA and earned a business degree from Wilfrid Laurier University and a Master of Business Administration from York University. Geddes has consistently delivered value across multiple functions including business and corporate development, strategic and new product planning, marketing, sales, market access, and medical/clinical affairs. Tomalin has participated in the Regulatory Initiatives Advisory Committee for the Pharmaceutical Manufacturers Association Canada (PMAC). Tomalin is a graduate of York University with a BA in English and BSc in Chemistry and holds certifications from the Regulatory Affairs Professional Society in US, European, and Canadian Regulatory Affairs.